Merkle E, Seidl C, Fuchs U, Sauerbrei W, Wirtz P M
Universitätsfrauenklinik Erlangen.
Geburtshilfe Frauenheilkd. 1990 Mar;50(3):215-9. doi: 10.1055/s-2007-1026466.
Adjuvant CMFV therapy was administered from 1975 to 1984 at the Department of Gynaecology and Obstetrics of the University of Erlangen in 331 patients from a patient population, who underwent an operation with the intention of curing invasive breast cancer. Six cycles of this therapy were administered to 224 women. Only these patients were considered in the evaluation. 538 patients without axillary lymph node metastases and without adjuvant therapy served as reference population. The significance of adjuvant CMFV therapy in relation to the lymph node and menopausal status was investigated in a retrospective analysis. It was shown, that the five-year actual survivals in the group of premenopausal patients with one to three affected lymph nodes and CMFV therapy (n = 60), did not differ significantly from the group of women with premenopausally negative lymph nodes without adjuvant therapy (n = 198) (87.7% versus 88.2%). On the other hand, in the postmenopausal patients, the five-year actual survivals for the corresponding groups were 65.9% and 83.2%, respectively. The difference was significant. The results indicate, that adjuvant CMFV therapy improves the prognosis in premenopausal women, above all in cases with one to three affected lymph nodes. In the postmenopausal patients, a comparable effect could not be demonstrated in this group of patients.
1975年至1984年期间，埃尔朗根大学妇产科对331例接受手术以治愈浸润性乳腺癌的患者实施了辅助性CMFV治疗。其中224名女性接受了六个疗程的该治疗。评估仅考虑这些患者。538例无腋窝淋巴结转移且未接受辅助治疗的患者作为对照人群。通过回顾性分析研究了辅助性CMFV治疗与淋巴结及绝经状态的相关性。结果显示，有1至3个受累淋巴结且接受CMFV治疗的绝经前患者组（n = 60）的五年实际生存率与未接受辅助治疗的绝经前淋巴结阴性女性组（n = 198）相比，无显著差异（87.7%对88.2%）。另一方面，在绝经后患者中，相应组的五年实际生存率分别为65.9%和83.2%。差异具有显著性。结果表明，辅助性CMFV治疗可改善绝经前女性的预后，尤其是在有1至3个受累淋巴结的病例中。在绝经后患者中，该组患者未显示出类似效果。
